Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration

Molecular Therapy

Volumn 2, Issue 4, 2000, Pages 374-380

  Lipshutz, Gerald S ^a   Flebbe Rehwaldt, Linda ^a   Gaensler, Karin M L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus; Fetus; Gene therapy; In utero; Luciferase

Indexed keywords

ADENOVIRIDAE; ANIMALIA;

BETA GALACTOSIDASE; LUCIFERASE; VIRUS ANTIBODY;

ADENOVIRUS; ANIMAL; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MOUSE; PREGNANCY; VIROLOGY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; BETA-GALACTOSIDASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNE TOLERANCE; LUCIFERASES; MALE; MICE; PREGNANCY;

EID: 0034294530     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0136     Document Type: Article

References (38)

1. Kass-Eisler, A., Leinwand, L., Gall, J., Bloom, B., and Falck-Pedersen, E. (1996). Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3: 154-162.
2. Smith, T. A., et al. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5: 397-402.
3. Mittal, S. K., McDermott, M. R., Johnson, D. C., Prevec, L., and Graham, F. L. (1993). Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res. 28: 67-90.
4. Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., and Verma, I. M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92: 1401-1405.
5. Harui, A., Suzuki, S., Kochanek, S., and Mitani, K. (1999). Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol. 73: 6141-6146.
6. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8: 37-44.
7. Nunes, F. A., Furth, E. E., Wilson, J. M., and Raper, S. E. (1999). Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration. Hum. Gene Ther. 10: 2515-2526.
8. Tripathy, S. K., Black, H. B., Goldwasser, E., and Leiden, J. M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2: 545-550.
9. Scharrer, I., Neutzling, O., Schwaab, R., Oldenburg, J., and Ehrlich, H. (1998). Experiences with recombinant factor VIII products: Development of inhibitors and immune tolerance therapy. Ann. Hematol. 76(Suppl. 1): A1-A6.
10. Cohen, A. J., and Kessler, C. M. (1996). Acquired inhibitors. Baillieres Clin. Haematol. 9: 331-354.
11. Mack, C. A., et al. (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8: 99-109.
12. Engelhardt, J. F., Ye, X., Doranz, B., and Wilson, J. M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc, Natl. Acad. Sci. USA 91: 6196-6200.
13. Morsy, M. A., et al. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95: 7866-7871.
14. Kay, M. A., et al. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration. Nat. Genet. 11: 191-197.
15. Zanjani, E. D., and Anderson, W. F. (1999). Prospects for in utero human gene therapy [see comments]. Science 285: 2084-2088.
16. Walsh, C. E. (1999). Perspective: Fetal gene therapy. Gene Ther. 6: 1200-1201.
17. Senut, M. C., and Gage, F. H. (1999). Prenatal gene therapy: Can the technical hurdles be overcome? Mol. Med. Today 5: 152-156.
18. Vincent, M. C., Trapnell, B. C., Baughman, R. P., Wert, S. E., Whitsett, J. A., and Iwamoto, H. S. (1995). Adenovirus-mediated gene transfer to the respiratory tract of fetal sheep in utero. Hum. Gene Ther. 6: 1019-1028.
19. Lipshutz, G. S., Flebbe-Rehwaldt, L., and Gaensler, K. M. (1999). Adenovirus-mediated gene transfer in the midgestation fetal mouse. J. Surg. Res. 84: 150-156.
20. McCray, P. B., Jr., et al. (1995). Adenoviral-mediated gene transfer to fetal pulmonary epithelia in vitro and in vivo. J. Clin. Invest. 95: 2620-2632.
21. Holzinger, A., Trapnell, B. C., Weaver, T. E., Whitsett, J. A., and Iwamoto, H. S. (1995). Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Pediatr. Res. 38: 844-850.
22. Douar, A. M., Adebakin, S., Themis, M., Pavirani, A., Cook, T., and Coutelle, C. (1997). Fetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther. 4: 883-890.
23. Woo, Y. J., Raju, G. P., Swain, J. L., Richmond, M. E., Gardner, T. J., and Balice-Gordon, R. J. (1997). In utero cardiac gene transfer via intraplacental delivery of recombinant adenovirus. Circulation 96: 3561-3569.
24. Lipshutz, G. S., Flebbe-Rehwaldt, L., and Gaensler, K. M. (1999). Adenovirus-mediated gene transfer to the peritoneum and hepatic parenchyma of fetal mice in utero. Surgery 126: 171-177.
25. Lipshutz, G. S., Sarkar, R., Flebbe-Rehwaldt, L., Kazazian, H., and Gaensler, K. M. (1999). Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc. Natl. Acad. Sci. USA 96: 13324-13329.
26. Addison, C. L., Hitt, M., Kunsken, D., and Graham, F. L. (1997). Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J. Gen. Virol. 78: 1653-1661.
27. Chardonnet, Y., and Dales, S. (1970). Early events in the interaction of adenoviruses with HeLa cells. I. Penetration of type 5 and intracellular release of the DNA genome. Virology 40: 462-477.
28. Hitt, M., Bett, A. J., Prevec, L., and Graham, F. L. (1994). Construction and propagation of human adenovirus vectors. In Cel Biology: A Laboratory Manual (J. E. Celis, Ed.), Vol. 2, pp. 479-490. Academic Press, San Diego.
29. Lowry, O. H., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275.
30. Osborn, M., and Isenberg, S. (1994). Immunocytochemistry of frozen and of paraffin tissue sections. In Cell Biology: A Laboratory Manual (J. E. Celis, Ed.), pp. 361-367. Academic Press, San Diego.
31. Liu, Y., et al. (1999). Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem. 274: 13338-13344.
32. Glantz, S. A. (1997). Primer of Biostatistics, 4th ed. McGraw-Hill, New York.
33. Barr, D., et al. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2: 151-155.
34. Yang, Y., Li, Q., Ertl, H. C., and Wilson, J. M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69: 2004-2015.
35. DeMatteo, R. P., Chu, G., Ahn, M., Chang, E., Barker, C. F., and Markmann, J. F. (1997). Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. J. Virol. 71: 5330-5335.
36. Michou, A. I., Santoro, L., Christ, M., Julliard, V., Pavirani, A., and Mehtali, M. (1997). Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4: 473-482.
37. Camargo, F., et al. (2000). Adenovirus-transgenic mice: Partial embryonic lethality and lack of immunological tolerance to adenoviral vectors. Mol. Ther. 1, Abstract #478.
38. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.